EP0289584A4 - Wundheilung und knochenregeneration. - Google Patents

Wundheilung und knochenregeneration.

Info

Publication number
EP0289584A4
EP0289584A4 EP19870907900 EP87907900A EP0289584A4 EP 0289584 A4 EP0289584 A4 EP 0289584A4 EP 19870907900 EP19870907900 EP 19870907900 EP 87907900 A EP87907900 A EP 87907900A EP 0289584 A4 EP0289584 A4 EP 0289584A4
Authority
EP
European Patent Office
Prior art keywords
pdgf
igf
purified
growth factor
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19870907900
Other languages
English (en)
French (fr)
Other versions
EP0289584A1 (de
EP0289584B1 (de
Inventor
Harold C Antoniades
Ray C Williams
Samuel E Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Institute of Molecular Biology Inc
Original Assignee
Harvard College
Institute of Molecular Biology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Institute of Molecular Biology Inc filed Critical Harvard College
Priority to AT87907900T priority Critical patent/ATE88899T1/de
Publication of EP0289584A1 publication Critical patent/EP0289584A1/de
Publication of EP0289584A4 publication Critical patent/EP0289584A4/de
Application granted granted Critical
Publication of EP0289584B1 publication Critical patent/EP0289584B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to healing wounds.
  • Growth factors are polypeptide hormones which stimulate a defined population of target cells.
  • growth factors include platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor beta (TGF- ⁇ ), epidermal growth factor (EGF), and fibroblast growth factor (FGF) .
  • PDGF is a cationic, heat-stable protein found in the granules of circulating platelets which is known to stimulate in vitro protein synthesis and collagen production by fibroblasts. It is also known to act as an in vitro mitogen and chemotactic agent for fibroblasts, smooth muscle cells, and glial cells.
  • the invention features, in one aspect, healing an external wound in a mammal, e.g., a human patient, by applying to the wound an effective amount of a composition that includes purified PDGF and purified IGF-I.
  • the composition aids in healing the wound, at least in part, by promoting the growth of epithelial and connective tissue and the synthesis of total protein and collagen. Wound healing using the composition of the invention is more effective than that achieved in the absence of treatment (i.e., without applying exogenous agents) or by treatment with purified PDGF alone, or purified IGF-I alone.
  • the invention features regenerating bone of a mammal, e.g., a human patient, by administering to the patient, preferably by application to the area of injured or depleted bone, an effective amount of a composition that includes purified PDGF and purified IGF-I.
  • the composition aids in regeneration, at least in part, by promoting the growth of connective tissue, bone, and cementum, and by stimulating protein and coll gen synthesis. Regeneration using the composition of the invention is more effective than that achieved in the absence of treatment (i.e., without - 3 -
  • the composition is prepared by combining, in a pharmaceutically acceptable carrier substance, e.g., commercially available inert gels or liquids (e.g., saline supplemented with albumin or methyl cellulose), purified PDGF and IGF-I (both of which are commercially available). Most preferably purified PDGF and IGF-I are combined in a weight-to-weight ratio of between 1:4 and 25:1, preferably between 1:2 and 10:1, and more preferably 1:1 or 2:1.
  • the purified PDGF and IGF-I may be obtained from human platelets or by recombinant DNA technology.
  • PDGF platelet-derived and recombinant materials of mammalian, preferably primate, origin; most preferably, the primate is a human, but can also be a chimpanzee or other primate.
  • Recombinant PDGF can be recombinant heterodimer, made by inserting into cultured prokaryotic or eukaryotic cells DNA sequences encoding both subunits, and then allowing the translated subunits to be processed by the cells to form heterodimer, or DNA encoding just one of the subunits (preferably the beta or "2" chain) can be inserted into cells, which then are cultured to produce homodimeric PDGF (PDGF-1 or PDGF-2 homodi er) .
  • PDGF-1 or PDGF-2 homodi er homodimeric PDGF
  • purified refers to PDGF or IGF-I which, prior to mixing with the other, is 95% or greater, by weight, PDGF or IGF-I, i.e., is substantially free of other proteins, lipids, and carbohydrates with which it is naturally associated. - 4 -
  • a purified protein preparation will generally yield a single major band on a polyacrylamide gel for each subunit of PDGF or IGF-I.
  • the purified PDGF or IGF-I used in the compositions of the invention is pure as judged by amino-terminal amino acid sequence analysis.
  • the composition of the invention provides a fast, effective method for healing external wounds of mammals, e.g., bed sores, lacerations and burns.
  • the composition enhances connective tissue formation compared to natural healing (i.e. no exogenous agents added) or pure PDGF or IGF-I alone.
  • the composition promotes about a 250% increase in new connective tissue and about a 95% increase in the growth of epithelial tissue.
  • the epithelial layer obtained is thicker than that created by natural healing, and also contains more epithelial projections connecting it to the new connective tissue; it is thus more firmly bound and protective. In addition, scar formation is minimized.
  • the composition of the invention also provides a fast, effective method for regeneration of connective tissue and bone of mammals, e.g., humans, with a history of peridontal disease.
  • the composition enhances connective tissue and bone formation compared to natural healing (i.e. no exogenous agents added) or pure PDGF or IGF-I alone.
  • IGF-I is commercially available from Amgen Corporation (Thousand Oaks, CA) and Kabi (Sweden).
  • Purified recombinant PDGF and purified PDGF derived from human platelets are commercially available from PDGF, Inc. (Boston, MA) , collaborative Research (Waltham, MA), and Amgen Corp. (Thousand Oaks, CA) .
  • Purified PDGF can also be prepared as follows:
  • the extracts are combined and dialyzed against 0.08M NaCl-O.OlM sodium phosphate buffer (pH 7.4) and mixed overnight at 4°C with CM-Sephadex C-50 equilibrated with the buffer. The mixture is then poured into a column (5 x 100 cm), washed extensively with 0.08M NaCl-O.OlM sodium phosphate buffer (pH 7.4), and eluted with 1M NaCl while 10 ml fractions are collected.
  • Active fractions are pooled and dialyzed against 0.3M NaCl-O.OlM sodium phosphate buffer (pH 7.4), centrifuged, and passed at 4°C through a 2.5 x 25 cm column of Blue Sepharose (Pharmacia) equilibrated with 0.3M NaCl-O.OlM sodium phosphate buffer (pH 7.4). The column is then washed with the buffer and partially purified PDGF eluted with a 1:1 solution of IM NaCl and ethylene glycol.
  • the partially purified PDGF fractions are diluted (1:1) with IM NaCl, dialyzed against IM acetic acid, and lyophilized.
  • the lyophilized samples are dissolved in 0.8M NaCl-O.OlM sodium phosphate buffer (pH 7.4) and passed through a 1.2 x 40 cm column of CM-Sephadex C-50 equilibrated with the buffer.
  • PDGF is then eluted with a NaCl gradient (0.08 to IM) .
  • the active fractions are combined, dialyzed against IM acetic acid, lyophilized, and dissolved in a small volume of IM acetic acid. 0.5 ml portions are applied to a 1.2 x 100 cm column of Biogel P-150 (100 to 200 mesh) equilibrated with IM acetic acid. The PDGF is then eluted with IM acetic acid while 2 ml fractions are collected.
  • Each active fraction containing 100 to 200 mg of protein is lyophilized, dissolved in 100 ml of 0.4% trifluoroacetic acid, and subjected to reverse phase high performance liquid chromatography on a phenyl Bondapak column (Waters). Elution with a linear acetonitrile gradient (0 to 60%) yields pure PDGF.
  • PDGF made by recombinant DNA technology can be prepared as follows:
  • PDGF Platelet-derived growth factor
  • PDGF-l is encoded by a gene localized in chromosome 7 (Betsholtz, C. et al.. Nature 320:695-699)
  • PDGF-2 is encoded by the sis oncogene (Doolittle, R. et al. (1983) Science 221:275-277) localized in chromosome 22 (Dalla-Favera, R. (1982) Science 218:686-688) .
  • the sis gene encodes - 7 -
  • SSV Simian Sarcoma Virus
  • the human cellular c-sis also encodes the PDGF-2 chain (Rao, CD. et al. (1986) Proc. Natl. Acad. Sci. USA 83:2392-2396).
  • human PDGF consists of a disulfide-linked heterodimer of PDGF-l and PDGF-2, or a mixture of the two homodimers (homodimer of PDGF-l and homodimer of PDGF-2), or a mixture of the heterodimer and the two homodimers.
  • the functional properties of the secreted PDGF-2 homodimer are similar to those of platelet-derived PDGF in that it stimulates DNA synthesis in cultured fibroblasts, it induces phosphorylation at the tyrosine residue of a 185 kd cell membrane protein, and it is capable of competing
  • sis/PDGF-2 gene product derived from cultured normal human cells (for example, human arterial endothelial cells), or from human malignant cells expressing the sis/PDGF-2 gene (Antoniades, H. et al. (1985) Cancer Cells 3:145-151).
  • the recombinant PDGF-2 homodimer is obtained by the introduction of cDNA clones of c-sis/PDGF-2 gene into mouse cells using an expression vector. .
  • c-sis/PDGF-2 clone used for the expression was obtained from normal human cultured endothelial cells (Collins, T., et al. (1985) Nature 216:748-750). Wound Healing
  • Wounds measuring 1 cm x 2 cm were induced at a depth of 0.5 mm using a modified Castroviejo electrokeratome (Storz, St. Louis, MO, as modified by Brownells, Inc.). The wounds resulted in complete removal of the epithelium, as well as a portion of the underlying dermis (comparable to a second degree burn injury) . Individual wounds were separated by at least 15 mm of unwounded skin. Wounds receiving identical treatment were organized as a group and separated from other groups by at least 3 cm. Wounds receiving no growth factor treatment were separated from wounds receiving such treatment by at least 10 cm.
  • the wounds were treated directly with a single application of the following growth factors suspended in biocompatible gel: 1) 500 ng pure human PDGF (purified by high performance liquid chromatography) or recombinant PDGF alone; 2) 500 ng pure PDGF in combination with each of the following: a) 500 ng EGF; b) 500 ng EGF plus 500 ng IGF-I; c) 500 ng IGF-I.
  • biopsy specimens were taken on days 3 through 10. .Biopsy specimens for histologic evaluation were taken as wedges approximately 3 mm deep and placed in 10% formalin. Specimens for biochemical analysis and autoradiography were obtained using an electrokeratome. The final dimensions of the specimens were 1.5 mm x 10 mm x 1.5 mm.
  • Biopsy specimens were incubated in 0.3 ml Eagle's Modified Essential Medium (EMEM) plus 10% fetal calf serum containing 15 ⁇ Ci/ml of H-thymidine for one hour; the specimens were then washed twice with 10% formalin.
  • EMEM Eagle's Modified Essential Medium
  • Four micron sections were made from the specimens using standard paraffin impregnating and embedding techniques. They were then deparaffinized, dipped in Nuclear Tract emulsion NTB-2 (Kodak), and exposed for two weeks. Subsequently, they were developed and stained with hematoxylin and eosin.
  • Histologic specimens were prepared using standard paraffin impregnating and embedding techniques. Four micron sections were made and stained using filtered Harris hemotoxylin and alcoholic eosin; they were then observed under a microscope. All specimens were scored blindly by two investigators at equally distributed points throughout the sections. The widths of the epithelial and connective tissue layers were scored using a grid placed within the ocular of the microscope; the measurement was then converted into millimeters using a micrometer viewed under the same conditions.
  • Biopsy specimens were transferred to individual tubes containing 0.3 ml of EMEM plus 10% fetal calf serum, 15 ⁇ Ci/ml H-thymidine, and 5 ⁇ Ci/ml
  • DNA determination was performed using a modification of the method of Labarca et al. (1980) Anal. Biochem. 120:344-52.
  • a 50 ⁇ l aliquot of tissue extract in concentrated ammonium hydroxide was added to 400 ⁇ l of a buffer solution containing 1 M sodium phosphate and 2M sodium chloride (pH 7.0); the pH of the resulting solution was adjusted to 7.4 using HC1. Afterwards, the final solution volume was brought to 500 ⁇ l, while maintaining the pH at 7.4.
  • Protein content of the tissue extract in concentrated ammonium hydroxide was measured by the Bradford method (Bradford (1976) Anal. Biochem. 72:248-54), with bovine serum albumin as a standard. Results
  • Metabolic labelling results showed that the uptake of 3 H-thymidine and C-leucine was greater for wounds treated with purified PDGF/IGF-I preparations than for wounds receiving no treatment; the PDGF/IGF-I-treated wounds similarly had greater DNA and protein contents.
  • PDGF-2 in combination with IGF-I resulted in 75% increases in both the new connective tissue and epidermal layers.
  • the connective tissue of PDGF-2/IGF-I treated wounds had definite areas of polarization of light indicating these wounds contained more mature connective tissue than either wounds receiving PDGF-2 alone or no treatment.
  • recombinant PDGF-2 to wound healing using the animal model described above, produces results similar to those with purified human PDGF when combined with recombinant IGF-I.
  • the combination of recombinant PDGF-2 and IGF-I produces dramatic increases in ths number of new fibroblasts and the rate of collagen syn-hesis, accompanied by hyperplasia of the der ii and epidermis (2.5-fold total increase) compared to th * control animal in the absence of treatment or by treat. ⁇ ent with recombinant PDGF-2 or IGF-I alone.
  • Beagle dogs with naturally occurring periodontal disease were selected on the basis of an initial radiographic examination.
  • the teeth which exhibited 30% to 80% bone loss were initially scaled using ultrasonic. instruments.
  • Surgical flaps and root planing techniques were then performed, and the experimental teeth were treated with a composition containing purified PDGF and IGF-I in a pharmaceutically acceptable carrier substance, e.g., commercially available inert gels, e.g., methyl cellulose.
  • Teeth in the remaining quadrants received control gel alone, or pure PDGF or IGF-I alone.
  • Block biopsies of the teeth and bone were taken at two weeks postsurgery and prepared for histologic evaluation using standard demineralizing and processing techniques. Results
  • results of histologic analysis of periodontal and bone specimens indicated that, adjacent to the root surfaces of experimental specimens (i.e., those treated with the PDGF/IGF-I combination) , distinct areas of new bone formation were present and a deposit resembling 88/034
  • cementu was present on the root surface adjacent to the new bone.
  • New bone was also present on the periosteal surface of the specimens, and areas of ankylosis had occurred within the apical extent of the ligament.
  • a dense layer of osteoblast-like cells, and connective tissue lined the newly formed bone with newly formed collagen fibers inserting into the newly formed cementum.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP87907900A 1986-11-14 1987-11-13 Wundheilung und knochenregeneration Expired - Lifetime EP0289584B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87907900T ATE88899T1 (de) 1986-11-14 1987-11-13 Wundheilung und knochenregeneration.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93076286A 1986-11-14 1986-11-14
US930762 1986-11-14

Publications (3)

Publication Number Publication Date
EP0289584A1 EP0289584A1 (de) 1988-11-09
EP0289584A4 true EP0289584A4 (de) 1990-01-08
EP0289584B1 EP0289584B1 (de) 1993-05-05

Family

ID=25459724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87907900A Expired - Lifetime EP0289584B1 (de) 1986-11-14 1987-11-13 Wundheilung und knochenregeneration

Country Status (15)

Country Link
EP (1) EP0289584B1 (de)
JP (1) JPH01500199A (de)
KR (1) KR960005708B1 (de)
CN (1) CN1027346C (de)
AT (1) ATE88899T1 (de)
AU (1) AU600069B2 (de)
DE (1) DE3785758T2 (de)
DK (1) DK175889B1 (de)
IE (1) IE60517B1 (de)
MX (1) MX170454B (de)
NO (1) NO883127L (de)
NZ (1) NZ222551A (de)
OA (1) OA09159A (de)
WO (1) WO1988003409A1 (de)
ZA (1) ZA878566B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889919A (en) * 1986-08-13 1989-12-26 Zymogenetics, Inc. Biologically active PDGF derived A-chain homodimers
US5474982A (en) * 1986-08-13 1995-12-12 Zymogenetics, Inc. PDGF analogs and methods of use
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
IL95641A0 (en) * 1989-09-15 1991-06-30 Curative Tech Inc Preparation of a platelet releasate product
ZA9010332B (en) * 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
WO1991015231A1 (en) * 1990-04-10 1991-10-17 Institute Of Molecular Biology, Inc. Wound healing
ATE222117T1 (de) * 1990-05-30 2002-08-15 Harvard College Kombination aus igf-i und tgf-beta zur knochenregenerierung
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7196054B1 (en) 1990-11-27 2007-03-27 The American National Red Cross Methods for treating wound tissue and forming a supplemented fibrin matrix
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
FR2691911B1 (fr) * 1992-06-05 1994-11-25 Delmas Olivier Dispositif permettant l'obtention d'un surnageant de thrombocytes activés, procédé mettant en Óoeuvre le dispositif et surnageant obtenu.
CA2114419A1 (en) * 1992-06-08 1993-12-23 Peter D. Gluckman Use of growth factor igf-i and/or igf-ii
FR2696095B1 (fr) * 1992-09-30 1994-11-25 Inoteb Colle biologique à base de protéines coagulables par la thrombine, enrichie en facteurs plaquettaires, sa préparation et son application.
CN1055023C (zh) * 1993-01-03 2000-08-02 周至譓 伤口护理剂
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
NZ271488A (en) 1994-07-12 1998-01-26 Human Genome Sciences Inc Connective tissue growth factor-2 (ctgf-2)
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
ES2293137T3 (es) * 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
ATE253120T1 (de) 1996-12-13 2003-11-15 Chiron Corp Verfahren zur expression von heterologen proteinen in hefe
US6663870B2 (en) 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7241874B2 (en) 2002-06-26 2007-07-10 Zimmer Ortho Biologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
EP1951327A2 (de) 2005-11-17 2008-08-06 Biomimetic Therapeutics, Inc. Kiefer- und gesichtsknochenerweiterung mithilfe von rhpdgf-bb und einer biokompatiblen matrix
EP2311505B1 (de) 2006-02-09 2013-11-06 BioMimetic Therapeutics, LLC Zusammensetzungen und Verfahren zur Behandlung von Knochen
AU2007269712B2 (en) 2006-06-30 2013-02-07 Biomimetic Therapeutics, Llc PDGF-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
JP5552315B2 (ja) 2006-11-03 2014-07-16 バイオミメティック セラピューティクス， エルエルシー アースロデティック術のための組成物および方法
CN102014977B (zh) 2008-02-07 2015-09-02 生物模拟治疗有限责任公司 用于牵引成骨术的组合物和方法
NZ591338A (en) 2008-09-09 2013-02-22 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
CN107080834A (zh) 2010-02-22 2017-08-22 生物模拟治疗有限责任公司 用于治疗腱病的血小板衍生生长因子组合物和方法
CN102397534B (zh) * 2010-09-07 2013-10-23 中国人民解放军总医院 胰岛素在制备促进颌骨组织愈合的药物中的用途
WO2013077641A1 (ko) * 2011-11-22 2013-05-30 (주)아모레퍼시픽 성장 인자를 포함하는 피부 재생 촉진제
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479896A (en) * 1981-12-11 1984-10-30 Antoniades Harry N Method for extraction localization and direct recovery of platelet derived growth factor

Also Published As

Publication number Publication date
DK393288D0 (da) 1988-07-14
CN1027346C (zh) 1995-01-11
MX170454B (es) 1993-08-24
EP0289584A1 (de) 1988-11-09
WO1988003409A1 (en) 1988-05-19
IE873075L (en) 1988-05-14
DK175889B1 (da) 2005-05-30
CN87101250A (zh) 1988-06-08
EP0289584B1 (de) 1993-05-05
AU8328987A (en) 1988-06-01
NO883127D0 (no) 1988-07-13
ZA878566B (en) 1989-07-26
OA09159A (en) 1992-03-31
ATE88899T1 (de) 1993-05-15
DE3785758D1 (de) 1993-06-09
NZ222551A (en) 1989-11-28
DE3785758T2 (de) 1993-08-05
JPH01500199A (ja) 1989-01-26
DK393288A (da) 1988-09-13
KR960005708B1 (ko) 1996-05-01
JPH0581569B2 (de) 1993-11-15
IE60517B1 (en) 1994-07-27
AU600069B2 (en) 1990-08-02
KR890700033A (ko) 1989-03-02
NO883127L (no) 1988-09-12

Similar Documents

Publication Publication Date Title
US4861757A (en) Wound healing and bone regeneration using PDGF and IGF-I
AU600069B2 (en) Wound healing and bone regeneration
US5019559A (en) Wound healing using PDGF and IGF-II
EP0394349B1 (de) Heilen von wunden
EP0382841B1 (de) Wundheilung
CA2040410C (en) Wound healing compositions containing il-1 and a growth factor
CA2060208C (en) Wound healing
US5256644A (en) Wound healing using IGF-II and TGF
CA2082420C (en) Wound healing composition comprising purified igf-i or igf-ii and a purified tgf-.beta.
AU613776B2 (en) Wound healing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19881117

A4 Supplementary search report drawn up and despatched

Effective date: 19900108

17Q First examination report despatched

Effective date: 19910313

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INSTITUTE OF MOLECULAR BIOLOGY, INC.

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO ROMA S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 88899

Country of ref document: AT

Date of ref document: 19930515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3785758

Country of ref document: DE

Date of ref document: 19930609

ET Fr: translation filed
EPTA Lu: last paid annual fee
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EAL Se: european patent in force in sweden

Ref document number: 87907900.2

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8328

Ref document number: 3785758

Country of ref document: DE

Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20061019

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20061117

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20061121

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20061122

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20061124

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061130

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20061204

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20061220

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20070102

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20070328

Year of fee payment: 20

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

BE20 Be: patent expired

Owner name: *INSTITUTE OF MOLECULAR BIOLOGY INC.

Effective date: 20071113

Owner name: *PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Effective date: 20071113

NLV7 Nl: ceased due to reaching the maximum lifetime of a patent

Effective date: 20071113

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20071113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20071112